News und Analysen
QIAGEN Increases Outlook for 2020 and 2021
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has raised its full-year 2020 outlook for growth of net sales and adjusted earnings per share (EPS) and is looking forward
QIAGEN hebt den Ausblick für 2020 und 2021 an
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass es den Ausblick für das Wachstum des Konzernumsatzes und den bereinigten Gewinn je Aktie (EPS) für das Gesamtjahr 2020
St. Luke’s University Health Network Wins 2020 Premier Alliance Excellence Award
Premier Inc. (NASDAQ: PINC) has named St. Luke’s University Health Network, a fully integrated, nationally recognized health network serving Pennsylvania and New Jersey, the winner of the 2020
AMN CEO Susan Salka Named One of Modern Healthcare’s 100 Most Influential People of 2020
Susan Salka, President and CEO of AMN Healthcare (NYSE:AMN), has been named by Modern Healthcare as one of 2020’s 100 Most Influential People. This year’s list focused on people who influenced the
LivaNova Announces Board Appointment and Board Leadership Changes
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a series of enhancements to the Company’s governance.
Todd Schermerhorn has been appointed
Xencor Enters Collaboration with Janssen with Aim to Discover Novel CD28 Bispecific Antibodies for the Treatment of Prostate Cancer
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced it has
Nanobiotix Announces the Start of the Roadshow for Its Proposed Global Offering and Proposed Nasdaq Listing
NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN : FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the start
Pfizer Reports Positive Clinical Data for BCMA-CD3 Bispecific Antibody (PF-06863135) in Multiple Myeloma
Pfizer Inc. (NYSE:PFE) today announced safety and clinical response results from the ongoing Phase 1 study (NCT03269136) for PF-06863135, an investigational B-cell maturation antigen (BCMA)
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x1013 VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy
Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene
QIAGEN to Launch QuantiFERON SARS-CoV-2 For Research Into Causes, Spread and Control of COVID-19 Through T-cell Response
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the launch of its QuantiFERON SARS-CoV-2 RUO solution that can detect T-cell responses of the human immune system to the
QIAGEN führt QuantiFERON SARS-CoV-2 ein, Test zur Erforschung von Ursachen, Verbreitung und Kontrolle von COVID-19 durch T-Zell-Reaktion
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Markteinführung der QuantiFERON SARS-CoV-2 RUO-Lösung bekannt, mit der T-Zell-Reaktionen des menschlichen Immunsystems auf den
Agilent Presents Thought Leader Award to IIT Delhi Scientist Professor Anurag Rathore
Agilent Technologies Inc. (NYSE: A) has honored Prof. Anurag Rathore, a scientist at the Indian Institute of Technology (IIT) Delhi, with an Agilent Thought Leader Award, for his contributions to
Xencor Presents Updated Data from the Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced updated data
Durable Clinical Benefits Induced by IMV’s T Cell Therapy in Combination With Merck’s Keytruda in Subjects With PD-L1 Positive r/r DLBCL Presented at ASH Annual Meeting
IMV Inc. (Nasdaq:IMV; TSX:IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases
LivaNova und Gyrus Capital schließen Vereinbarung über den Kauf des Herzklappengeschäfts
LivaNova PLC (NASDAQ:LIVN), ein marktführendes Medizintechnik- und Innovationsunternehmen, und Gyrus Capital (Gyrus), eine Investmentfirma, die sich auf Investitionen im Gesundheits- und
LivaNova to Host Satellite Symposium on Advances in Neuromodulation at American Epilepsy Society AES2020 Virtual Event
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it will host “Updates and Advances in Neuromodulation,” a satellite symposium at AES2020, the
Premier Inc. to Participate in the Guggenheim Digital Health Virtual Summit on December 8, 2020
Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, announced today that members of its management team are scheduled to participate in a fireside chat at the Guggenheim Digital
Transgene to Present Phase 1b/2 Trial Results of TG4001 in Combination with avelumab in Advanced HPV-Positive Cancers at ESMO IO 2020
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, will present the Phase 1b/2 trial results of TG4001, a HPV16
Transgene Appoints Hedi Ben Brahim as Chairman and Chief Executive Officer
Regulatory News:
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced that the Board, at its meeting today, approved the
AMN Healthcare Names James Taylor as Group President and Chief Operating Officer for Physician & Leadership Solutions
AMN Healthcare (NYSE: AMN) has named James Taylor as its new Group President and Chief Operating Officer for Physician & Leadership Solutions.
This press release features multimedia. View the full
DILIsym Services Presents Important DILIsym and NAFLDsym Software Applications at the Virtual AASLD Liver Meeting
DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that
Agilent Announces Alissa Interpret Selected by North West Genomic Laboratory Hub for Clinical Genomic Analysis
Agilent Technologies Inc. (NYSE: A) today announced its clinical informatics platform Alissa Interpret has been adopted by the North West Genomic Laboratory Hub (NW GLH) based in Manchester and
Eyenovia Announces FDA Acceptance of IND for MicroLine for Presbyopia, Clearing Path to Initiate Phase 3 VISION Trial by Year End
Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the U. S. Food and
IMV’s Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Patients with Hard-to-Treat Advanced Recurrent Ovarian Cancer
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of targeted cancer immunotherapies and vaccines against infectious diseases, today reports
Lantheus Holdings, Inc. Announces Agreement to Sell Its Puerto Rico Radiopharmacy and PET Manufacturing Facility and Enter into Long-Term Supply Agreement
Lantheus Holdings, Inc. (NASDAQ: LNTH) (the Company), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture